Impact of adverse events, treatment modifications, and dose intensity on survival among patients with advanced renal cell carcinoma treated with first-line sunitinib: a medical chart review across ten centers in five European countries

Angiogenesis inhibitors have become standard of care for advanced and/or metastatic renal cell carcinoma (RCC), but data on the impact of adverse events (AEs) and treatment modifications associated with these agents are limited. Medical records were abstracted at 10 tertiary oncology centers in Euro...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Cancer Med
Main Authors: Porta, Camillo, Levy, Antonin, Hawkins, Robert, Castellano, Daniel, Bellmunt, Joaquim, Nathan, Paul, McDermott, Ray, Wagstaff, John, Donnellan, Paul, McCaffrey, John, Vekeman, Francis, Neary, Maureen P, Diaz, Jose, Mehmud, Faisal, Duh, Mei Sheng
Formato: Artigo
Idioma:Inglês
Publicado em: Blackwell Publishing Ltd 2014
Assuntos:
Clinical Cancer Research
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4298378/
https://ncbi.nlm.nih.gov/pubmed/25045157
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cam4.302
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados